Article

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacy

2025-01-19

Abstract excerpt

TUB-010 is a next-generation antibody-drug conjugate (ADC) targeting CD30, which is expressed on various hematopoietic malignancies such as Hodgkin lymphoma and anaplastic large cell lymphoma. Patients with refractory and relapsed CD30-positive cancers often lack effective and tolerable therapy options. Among the therapeutic options for these patients is brentuximab vedotin (Adcetris), a monomethyl auristatin E (M...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c0c90c6c-cad6-502a-aa7b-4edd29b64152
DOI: 10.1101/2025.01.15.633119

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

TUB-010, a novel anti-CD30 antibody-drug conjugate based on Tub-tag technology, widens the therapeutic window by reducing toxicity while maintaining high efficacyDOI 10.1101/2025.01.15.633119Read

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical ProgressSemantic proximity Read

Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.Semantic proximity Read

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read

Antibody and antibody fragments Site Specific Conjugation using New Q-tag Substrate of Bacterial Transglutaminase.Semantic proximity Read

Current ADC Linker ChemistrySemantic proximity Read

Next generation of anti-PD-L1 Atezolizumab with better anti-tumor efficacy <i>in vivo</i>Semantic proximity Read

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and ResistanceSemantic proximity Read

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read

A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO)Semantic proximity Read

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomasSemantic proximity Read

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.Semantic proximity Read

GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activitySemantic proximity Read